GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (NAS:CTIC) » Definitions » Book Value per Share

CTI BioPharma (CTI BioPharma) Book Value per Share : $-0.19 (As of Mar. 2023)


View and export this data going back to 1997. Start your Free Trial

What is CTI BioPharma Book Value per Share?

CTI BioPharma's book value per share for the quarter that ended in Mar. 2023 was $-0.19.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CTI BioPharma was 92.60% per year. The lowest was -66.50% per year. And the median was 1.00% per year.

CTI BioPharma's current price is $9.09. Its book value per share for the quarter that ended in Mar. 2023 was $-0.19. Hence, today's PB Ratio of CTI BioPharma is .

During the past 13 years, the highest P/B Ratio of CTI BioPharma was 113.61. The lowest was 0.00. And the median was 3.57.


CTI BioPharma Book Value per Share Historical Data

The historical data trend for CTI BioPharma's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma Book Value per Share Chart

CTI BioPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.01 0.41 0.53 0.04 -0.13

CTI BioPharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.05 -0.13 -0.13 -0.19

Competitive Comparison of CTI BioPharma's Book Value per Share

For the Biotechnology subindustry, CTI BioPharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CTI BioPharma's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CTI BioPharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where CTI BioPharma's PB Ratio falls into.



CTI BioPharma Book Value per Share Calculation

CTI BioPharma's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-17.58-0.00)/130.75
=-0.13

CTI BioPharma's Book Value Per Share for the quarter that ended in Mar. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-25.35-0.00)/131.88
=-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


CTI BioPharma  (NAS:CTIC) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


CTI BioPharma Book Value per Share Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CTI BioPharma (CTI BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.
Executives
James K Fong officer: EVP & Chief Commercial Officer C/O CTI BIOPHARMA CORP, 3101 WESTERN AVENUE, SUITE 800, SEATTLE WA 98121
Adam R Craig director, officer: President and CEO C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
David Kirske officer: EVP, Chief Financial Officer C/O CTI BIOPHARMA CORP., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Michael A Metzger director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Matthew D Perry director ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Laurent Fischer director C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
David Ross Parkinson director C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Richard L Love director
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104